Tuesday 22nd November 2011
|Text too small?|
Cerebos New Zealand’s $71.6 million bid to buy Comvita undervalues the local honey products maker by as much as 38 percent, according to the independent adviser’s report.
Comvita’s independent directors are urging shareholders to reject the hostile bid, having previously called it an “unsolicited, unwelcome, opportunistic” offer.
Adviser Grant Samuel valued Comvita at between $3.40 and $4 a share, a premium of between 26 percent and 38 percent to Cerebos NZ’s $2.50 a share offer, and said there’s no compelling reason for investors to accept the bid.
“This is not the time to sell your Comvita shares,” chairman Neil Craig said in a statement. “If a buyer emerges willing to fully recognise the potential of Comvita, we will assess such an offer and report to shareholders.”
Since the offer emerged last month, the shares have climbed 38 percent to $2.90. That makes the offer a 16 percent discount to the current trading price.
Last week, Comvita reported a first-half profit of $2.2 million, turning around a loss of $2.2 million a year earlier.
The offer came a month after Comvita settled a patent dispute with Brightwake, where it granted a sub-licence to the British rival letting it manufacture, distribute and sell its Algivon brand in territories where the Comvita subsidiary Apimed Medial Honey has patent protections. As part of the settlement, Comvita avoided a 226,000 pound payment.
The Te Puke-based company expects annual profit of between $7.3 million and $8.2 million, with sales likely to be between $91 million and $95 million. In its bid, Cerebos pointed out Comvita had missed meeting forecast guidance in the past four financial years.
Cerebos NZ is the local bidding vehicle for Singapore-listed Cerebos Pacific, and will delist Comvita if it wins 90 percent of acceptances, the minimum level needed to force compulsory acquisition.
If it falls short but declares the bid unconditional with at least 50 percent of the company, it will “seek appropriate representation on the Comvita board and will participate in decisions relating to Comvita and its future through the Comvita board,” according to the offer document.
Sister company Cerebos Gregg’s, whose local brands include Caffe L’Affare coffee, Bisto gravies, and Raro drink powder, recently invested $13 million to expand facilities in a joint venture at Mount Maunganui, and is spending $6 million on the country’s only instant coffee producing plant in Dunedin.
Shares in Cerebos Pacific fell 1.5 percent S$4.60 on the Singapore Exchange in trading yesterday.
No comments yet
Comvita may not increase earnings in 2014 as higher honey prices bite, Craigs says
Comvita turned to a loss in first half, remains confident of increasing annual profit
Nasdaq-listed Derma Sciences takes 7.3 percent stake in Comvita in discounted placement
Comvita FY profit falls 10 percent , beating guidance, on honey shortage, rising costs
Comvita flags 15 percent fall in FY profit as expensive honey, supply shortages prompt downgrade
Comvita buys Aussie groves to expand olive extract output
Comvita first-half earnings fall 7.4% amid short supply
Comvita buys Whanganui-based Kiwi Honey for undisclosed sum
Comvita hits 5-yr high on early results from diabetes trial
Comvita to seek deeper pool for directors' fees at AGM